The FDA has approved the subcutaneous injection of nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for adults with solid tumors. This approval is based on the results of the CHECKMATE-67T study, showing a similar safety profile to the intravenous form of the drug. The drug is indicated for various cancers, including renal cell carcinoma, melanoma, and lung cancer. The recommended dosage varies depending on the indication. The trial included 495 patients with advanced clear cell renal cell carcinoma who showed a 24% overall response rate with the subcutaneous form. The most common adverse reactions included fatigue, musculoskeletal pain, and rash.
Source link
FDA approves Opdivo as subcutaneous injection
